UCB S.A. will acquire U.S.-based Ra Pharmaceuticals Inc. for $2.1 billion in an all cash deal.
Shareholders of Ra Pharma RARX, +0.33% will receive $48 for each share held, a joint statement by the two companies said Thursday.
The transaction has been unanimously approved by the boards the two companies, the statement said, adding the deal is expected to be completed in the first quarter next year after regulatory approvals.
UCB UCB, -0.25% will finance the acquisition via a combination of cash and loans.
Bank of America Merrill Lynch and Lazard were the financial advisors to UCB, while Ra Pharma was advised by Centerview Partners.
Ra Pharma is a biopharmaceutical company focused on rare diseases. Belgium-based UCB is also a biopharmaceutical company that focuses on severe diseases of the immune system or of the central nervous system.